The Ice House of Danbury serves as a local information hub for cancer, Alzheimer's and diabetes studies now available to residents of Greater New Milford and Greater Danbury.

The announcement was made recently by Rolf Martin of Sherman, who has been a principal investigator of the Connecticut-based Blueberry Health Study since 2002 while working at the Burke-Cornell Medical Research Institute and Burke Rehabilitation Hospital in White Plains, N.Y., as a statistician and artificial intelligence specialist.

The Ice House was chosen as an information hub because it provides both regular ice and dry ice needed for medical studies.

Research on cancer and Alzheimer's disease has been painfully slow for scientists as well as for people who fear these illnesses.

Now a road map of gene interactions has been developed that explains how cell protection can be increased as much as 1000-fold, Martin explained.

This new map connects diabetes, cancer and Alzheimer's research and offers new hope for progress on all three fronts.

At the center of this map is a gene product called "mechanistic target of rapamycin" or mTOR.

Interest in mTOR is so high that on average five new studies about it are listed in the U.S. National Institutes of Health database every day.

Rapamycin, the most extensively studied medicine that regulates mTOR, is now listed in 15,827 patents because it provides so many different health benefits. Metformin, the widely prescribed diabetes medication, is also at the center of this map.

L-Nutra, a company funded by the National Cancer Institute to manufacture and distribute anti-cancer food supplements, expects to have their first product ready for sale by the end of 2013. Their food supplement, called Chemolieve, is expected to help delay or prevent diabetes and Alzheimer's as well reduce chemotherapy side effects and help more patients to defeat cancer.

For more information about locally available health studies, call the Danbury Ice House at 203-792-2378 or visit